AI assistant
Cue Biopharma, Inc. — Director's Dealing 2019
Mar 8, 2019
34525_dirs_2019-03-08_af3bd5d2-cbc3-40ea-8d56-eeea64c19f62.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Cue Biopharma, Inc. (CUE)
CIK: 0001645460
Period of Report: 2019-03-06
Reporting Person: Sandercock Colin (SVP, General Counsel and Sec)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2019-03-06 | Stock Option (right to buy) | $6.42 | A | 50000 | Acquired | 2029-03-06 | Common Stock (50000) | Direct |
| 2019-03-06 | Stock Option (right to buy) | $7.50 | A | 100000 | Acquired | 2024-12-27 | Common Stock (100000) | Direct |
Footnotes
F1: This stock option grant becomes exercisable in eight equal semi-annual installments beginning September 6, 2019.
F2: Represents a stock option award granted on December 27, 2017 that partially vested upon the achievement of certain performance based conditions as determined by the Compensation Committee of Cue Biopharma, Inc. on March 6, 2019. As of March 6, 2019, 65,000 of these options were vested and exercisable. The remaining 35,000 will become vested and exercisable only upon the achievement of certain performance based conditions.